Aryx Therapeutics I Stock Fundamentals

ARYXDelisted Stock  USD 0.0005  0.00  0.00%   
Aryx Therapeutics I fundamentals help investors to digest information that contributes to Aryx Therapeutics' financial success or failures. It also enables traders to predict the movement of Aryx Pink Sheet. The fundamental analysis module provides a way to measure Aryx Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aryx Therapeutics pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Aryx Therapeutics I Company Number Of Shares Shorted Analysis

Aryx Therapeutics' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Shares Shorted

 = 

Shorted by Public

+

by Institutions

More About Number Of Shares Shorted | All Equity Analysis

Current Aryx Therapeutics Number Of Shares Shorted

    
  89.05 K  
Most of Aryx Therapeutics' fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aryx Therapeutics I is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Competition

Based on the recorded statements, Aryx Therapeutics I has 89.05 K of outstending shares currently sold short by investors. This is 97.22% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The number of shares shorted for all United States stocks is 98.11% higher than that of the company.

Aryx Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Aryx Therapeutics's current stock value. Our valuation model uses many indicators to compare Aryx Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aryx Therapeutics competition to find correlations between indicators driving Aryx Therapeutics's intrinsic value. More Info.
Aryx Therapeutics I is rated fifth in return on asset category among its peers. It also is rated fifth in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Aryx Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Aryx Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Aryx Number Of Shares Shorted Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aryx Therapeutics' direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aryx Therapeutics could also be used in its relative valuation, which is a method of valuing Aryx Therapeutics by comparing valuation metrics of similar companies.
Aryx Therapeutics is currently under evaluation in number of shares shorted category among its peers.

Aryx Fundamentals

About Aryx Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Aryx Therapeutics I's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aryx Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aryx Therapeutics I based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California. ARYX THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on PNK Exchange. It employs 56 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Consideration for investing in Aryx Pink Sheet

If you are still planning to invest in Aryx Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aryx Therapeutics' history and understand the potential risks before investing.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation